Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Top Biologic Industry Leaders to Convene at Biologics World Korea 2013

Published: Friday, December 07, 2012
Last Updated: Friday, December 07, 2012
Bookmark and Share
Bringing together biologics drug innovators and bioprocess professionals from all around the world to discuss strategies in biosimilar and biobetter development, as well as cutting-edge advances in bioprocessing and bioanalytics.

The global biologics market is valued at an estimated US$149 bn and is expected to reach $230 bn by 2015. Monoclonal antibodies (mAbs) representing 32% of the market share is expected to be the fastest growing segment at 12.4% CAGR. South Korea’s biologics industry is well positioned to tap into this growing market. While Celltrion, Samsung Biologics and LG Life Sciences are grabbing the international headlines, innovative firms in South Korea such as Genexine, PharmAbcine, Alteogen and Ildong are building up an impressive innovative biologic pipeline that can rival international players.

The biologics landscape in South Korea is evolving fast. Knowing the who's and understanding the how's of the industry are crucial to stay competitive. Biologics World Korea 2013 conference will convene all these biologic players from South Korea and around the globe, to discuss the trend and challenges in biologic drug development. The conference will be chaired by Dr Byeong Doo Song, the President of Scripps Korea Antibody Institute.

The conference Keynote speaker is Dr Stanley Hong, the President of R&D of Celltrion, who led the first mAb biosimilar approval in the world. He said that the company will be interested in developing Biobetters. The company just launched its product, RemsimaTM worldwide and has already signed several distribution agreements with several leading pharma companies.

Another featured speaker is Dr Paul Coleman, the CEO of Hanwha Biologics, who successfully led the company in making its first landmark deal to license its newly developed biosimilar compound to Merck. Dr Coleman said that a key criterion in making a biosimilar globally available through partnerships is having the highest standards of quality in all aspects of the research and development processes. This is the key to success for the interest of companies who can access global markets. Hanwha Biologics has already garnered the interest of top companies in the world for its portfolio of other biosimilar compounds and is seeking to expand through further research and development of future biosimilar candidates.

The 2013 conference programme features industry visionary presentations from the Celltrion, Hanwha Biologics, Green Cross, Genexine, SK Chemicals, CJ CheilJedang, Mogam Biotech Institute, UCB Korea, Neopharm, KAIST, KRIBB, KBSI, PhamAbcine, Creagene, Merck Serono (USA), Protein Science Corporation (USA), NovImmune (Switzerland), Actokine (USA), Quest Pharma Tech (Canada), Wuxi AppTech Biologics (China) and many more. The conference programme runs on April 16-18 2013 at Sheraton Incheon Hotel. Technology providers such as BD Bioscience, Waters Korea, Dong-Il Shimadzu, Agilent Technologies and many others will also be there to showcase the latest solutions.

Since the inaugural success of Biologics World Korea 2012, the year 2013 conference will be more comprehensive to include biologic players at various stages of development. In the near term future, the innovations and partnerships will continue to drive the activities in this industry. With networking opportunities, presentation of valuable case studies and interactive discussion, the Biologics community can look forward to a fruitful gathering at the Biologics World Korea 2013. This conference aims to capture a holistic view of the issues challenging the industry, from market landscape to regulatory strategy, from bioprocessing to bioanalytics, from antibody engineering to clinical development.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

IMAPAC to Bring Together Over 150 Leading Industry Players
IMAPAC’s 3rd Biologics Korea gathering from 22-24 April 2014 in Seoul, Korea.
Wednesday, February 19, 2014
Regional Health Authorities to Meet and Discuss Russia’s 2020 Vision
Government aims for 50% of sold drugs to be manufactured in Russia by 2020.
Thursday, September 05, 2013
Last Days of the Early Bird Pricings for Biologics World China 2012
Keep up to date with China’s changing biopharma landscape by registering for Biologics World China 2012.
Monday, September 24, 2012
Scientific News
New Vaccine For Chlamydia to Use Synthetic Biology
Prokarium Ltd, a biotechnology company developing transformational oral vaccines, have announced new funding from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology.
Researchers Discover Immune System’s 'Trojan Horse'
Oxford University researchers have found that human cells use viruses as Trojan horses, transporting a messenger that encourages the immune system to fight the very virus that carries it.
How to Become a Follicular T Helper Cell
Uncovering the signals that govern the fate of T helper cells is a big step toward improved vaccine design.
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!